Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 390 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Yeu Lin sold 390 shares of the firm’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $26,130.00. Following the completion of the transaction, the insider owned 23,308 shares in the company, valued at $1,561,636. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, March 18th, Elizabeth Yeu Lin sold 379 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $68.71, for a total transaction of $26,041.09.
• On Tuesday, March 17th, Elizabeth Yeu Lin sold 375 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $69.42, for a total transaction of $26,032.50.

Tarsus Pharmaceuticals Trading Down 2.2%

TARS traded down $1.49 during mid-day trading on Thursday, hitting $66.75. The stock had a trading volume of 461,600 shares, compared to its average volume of 672,393. The stock’s fifty day simple moving average is $69.36 and its 200-day simple moving average is $70.18. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -41.20 and a beta of 0.55. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The firm had revenue of $151.67 million during the quarter, compared to analyst estimates of $144.56 million. As a group, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on TARS shares. Mizuho assumed coverage on Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price target for the company. Zacks Research lowered Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Wall Street Zen cut Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Finally, Guggenheim lifted their price target on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.83.

Key Stories Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published a set of 2026 estimates that materially narrow expected losses (FY2026 now seen at -$1.01 vs. broader consensus -$3.17) and forecast a positive Q4‑2026 EPS of $0.09 — a clear bullish catalyst that can support upside expectations. Lifesci upgrade report
• Positive Sentiment: Large institutional investors have been increasing stakes (RTW, Deep Track, Jennison, Vanguard, Morgan Stanley among others), keeping roughly 90% institutional ownership — steady buying from big funds tends to support share-price stability and upside over time. MarketBeat TARS coverage
• Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable: the average recommendation is “Moderate Buy” and some firms (Guggenheim, Oppenheimer) have raised targets while others are more cautious — this keeps the outlook constructive but not unanimous. Analyst consensus article
• Neutral Sentiment: Recent quarterly results: revenue beat estimates ($151.7M vs. $144.6M) but EPS slightly missed ($0.20 loss vs. $0.19 expected). Revenue strength is supportive; continued negative margins and guidance keep risk elevated until pipeline milestones materialize. Earnings summary
• Negative Sentiment: Insider selling: Director William J. Link sold 12,500 shares at an average $68.79 on March 16 (disclosed via SEC filing), reducing his stake by ~9.7%. Insider sales can create short‑term downward pressure or be interpreted by some investors as profit‑taking. InsiderTrades report (SEC Form 4)

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Comerica Bank lifted its holdings in shares of Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after purchasing an additional 705 shares in the last quarter. Truvestments Capital LLC grew its holdings in shares of Tarsus Pharmaceuticals by 106.1% during the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock worth $74,000 after buying an additional 468 shares in the last quarter. Rockefeller Capital Management L.P. grew its holdings in shares of Tarsus Pharmaceuticals by 15.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after buying an additional 172 shares in the last quarter. Osaic Holdings Inc. raised its position in Tarsus Pharmaceuticals by 779.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after buying an additional 2,462 shares during the last quarter. Finally, Leonteq Securities AG acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at approximately $164,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.